Strategic partnership for advanced biomanufacturing Transcenta Therapeutics and EirGenix Inc. have entered into a strategic non-exclusive licensing agreement, granting EirGenix access to Transcenta’s Highly Intensified Continuous Bioprocessing (HiCB) platform. This partnership includes the transfer of high-productivity continuous perfusion and integrated hybrid continuous purification technologies, alongside comprehensive technical documentation and regulatory support.
In return, Transcenta is eligible for substantial upfront payments, milestone achievements, and future royalties associated with the commercial application of the licensed technology.
Advantages of the HiCB platform over conventional methods The HiCB platform is engineered to transcend the limitations of traditional fed-batch manufacturing. Key benefits include:
-
Process efficiency: Optimizing equipment utilization and accelerating production timelines.
-
Enhanced control: Improving product consistency through real-time process monitoring.
-
Cost reduction: Significantly lowering the cost of goods (COGS), ultimately facilitating broader global patient access to affordable, high-quality biologics.
Expanding CDMO capabilities EirGenix plans to integrate the HiCB platform into its internal biologics development programs and its manufacturing operations. A primary focus will be serving CDMO clients seeking intensified and continuous manufacturing solutions. This collaboration merges Transcenta’s technological innovation with EirGenix’s proven bioprocessing expertise to establish a more efficient and sustainable standard for biologics production worldwide.
Source: